July 6, 2020
(To join our email list, click here.)
In this article, I report on what is apparently a hereditary condition. Modern researchers would call it genetic in nature. I’m not endorsing their analysis or conclusion. All I’m saying is: apparently hereditary. This article is not intended as a single explanation for all patients who are experiencing severe shortage of oxygen. It is offered as one potential reason.
Imagine this. A person has a hereditary disorder that breaks apart some red blood cells and makes them less able to transport oxygen throughout the body.
Fortunately, the disorder isn’t that serious. The person lives with it.
BUT about 40 medical drugs can rapidly intensify this disorder, making it far worse. Making the oxygen shortage severe and acute. Even lethal.
The most dangerous of these 40 drugs? The ones given to prevent malaria.
Such as hydroxychloroquine. HCQ.
Getting the picture so far?
We’re told that many millions of people of African and Eastern Mediterranean descent have this hereditary disorder.
Therefore, if they’re given HCQ in, say, a clinical trial, or at a clinic or hospital, the result could be death.
Encyclopedia Britannica: “Glucose-6-phosphate dehydrogenase deficiency, hereditary metabolic defect characterized by an increased tendency of the red blood cells to break and release their hemoglobin (hemolysis), especially after the intake of certain drugs. The condition is caused, as the name indicates, by the markedly reduced activity in the red blood cells of a particular organic catalyst, or enzyme, called glucose-6-phosphate dehydrogenase. This low enzyme activity is associated with a decrease in the formation of certain substances that normally help to prevent the oxidative destruction of the red blood cell membrane. Under normal conditions, the affected red blood cells are only slightly more fragile than usual, but more than 40 drugs, including chloramphenicol and sulfonamides, all of which are converted in the body to oxidant compounds, have been shown to produce hemolysis in susceptible persons. There seem to be several variants of the disorder, all of which appear to be sex-linked and fully expressed in males only [a debatable assertion]. The most common form is found chiefly in persons whose ancestors inhabited either Africa or the Eastern Mediterranean basin. A possible protective effect of this metabolic abnormality against malaria has been suggested.”
I was alerted to this information by an article posted at off-guardian.org, by Dr. Wolfgang Wodarg: “COVID-19: A case for medical detectives.” Among many other points, Dr. Wodarg mentions that major clinical trials of HCQ are failing to screen volunteers for the heredity disorder which would make it exceedingly dangerous for them to be given the drug.
And how many patients showing up at hospitals all over the world already have this blood disorder, at a very serious level, AS A RESULT OF PREVIOUSLY TAKING ANY OF THE 40 DRUGS WHICH INTENSIFY THE SHORTNESS OF OXYGEN?
In the literature I’ve come across, there are somewhat different assessments of which groups are most prone to having the hereditary disorder. Here is a sample: “[The condition] affects individuals of all races and ethnic backgrounds. The highest prevalence rates are found in Africa, the Middle East, certain parts of the Mediterranean, and certain areas in Asia. In these regions, the rate ranges from 5% to 30% of the population. The severity…can vary based upon specific racial groups. The severe form of the disorders occurs more often in the Mediterranean population…Another…variant is found particularly among individuals of Sephardic Jewish or Sardinian descent. In addition, another somewhat common variant is present among some individuals of southern Chinese descent.”
Dr. Wodarg, referenced above, published a letter in the bmj online journal, in April, titled, “Chloroquine and Hydroxychloroquine in covid-19: “Chloroquine may kill many people in Africa, Italy, New York and elsewhere…”
“…I worked in a clinic for tropical medicine (Bernhard-Nocht-Institute, Hamburg) and later visited several countries in Africa to see a lot of health care facilities working hard with little resources. Malaria and anti-malaria drugs were always a main topic.”
“When I noticed that WHO and many others advocate the use of hydroxychloroquine (HCQ), if the SARS-CoV-2 test is positive, I was astonished to meet the drug in this context again.”
“HCQ is an old malaria drug, used also with autoimmune diseases but is not yet officially approved for Covid-19. The recently registered studies with HCQ (I found more than 100 on 18/4/2020, 35 new ones last week (1)) also want to use HCQ alone or in combination with other drugs. HCQ has already been ‘compassionately’ used in some countries even without the framework of a clinical study.”
“…However, HCQ was a long time ago identified to be one of the drugs (3) that cause severe damage to erythrocytes in cases of hereditary glucose-6-phosphate dehydrogenase (G6PD) deficiency [the hereditary disorder I’m discussing in this article].”
“As an effect of HCQ in those patients we see haemolysis. Erythrocytes burst en masse. Their debris clogs the smallest blood vessels and damages sensitive organs like the kidneys and brain.”
“In addition, erythrocytes are then missing to transport oxygen and haemoglobin becomes low. If people with G6PD deficiency get this HCQ-prophylaxis or therapy the symptoms will appear soon.”
“1-2 days after the start of such treatment a very severe clinical picture with weakness, dizziness, respiratory distress and signs of organ damage develops.”
“This may end in death if the toxic medication is not stopped immediately.”
“Could it be one reason for those cases where severe shortness of breath was observed without typical signs of pneumonia. It is a clinical picture ‘as if the patient suddenly was dropped out on top of the Himalayas’, said one of the New York ICU-doctors…”
What about, for example, Africans living in Africa? Haven’t they been taking anti-malaria drugs for decades? Since many of these people (millions) have this hereditary disorder, why haven’t we heard of mass catastrophes?
After coming up empty in a number of searches, I sought the advice of a physician who is familiar with the subject. His answer was:
“…Although people living in Africa do take them [the anti-malaria drugs], [they use them] significantly less compared to visitors or expats from the West. However the fundamental question is the dosage. This [dosage] seems to be significantly higher in treatments against Covid-19 compared to malaria treatment…”
As Dr. Wodarg mentions, he sees no evidence that people in clinical trials of HCQ are being pre-screened for the hereditary disorder.
Several days ago, I wrote an article about the discoveries of Dr. Meryl Nass, who has investigated several major current clinical trials of HCQ. She discovered the dosage levels were huge, even lethal.
More medical crime, more death.
SOURCES:
